AACR Preview
Investigators from the UCLA Health Jonsson Comprehensive Cancer Center will discuss the latest breakthroughs and cutting-edge science…
Browsing: Featured Events
Addition of atezolizumab to chemotherapy after surgery does not improve survival for triple negative breast cancer
Patients with triple-negative breast cancer do not benefit from the addition of atezolizumab to their…
Breast cancer patients can safely avoid extensive removal of lymph nodes if they respond well to primary systemic treatment
Patients with breast cancer that has started to spread to the lymph nodes in the…
Exercise helps patients with advanced breast cancer, especially if they are suffering with pain
Taking part in an exercise programme reduced pain and fatigue, and improved quality of life…
ASCO GU 2024: Subcutaneous nivolumab as effective as IV for renal cell carcinoma with much faster treatment time
Subcutaneous injection of the immunotherapy nivolumab is non-inferior to intravenous delivery and dramatically reduces treatment…
ASCO GI 2024: New study adds to ambiguity of role of post-operative ctDNA to guide treatment in patients with low-risk, stage IIA colon cancer
The role of ctDNA, or liquid biopsy, as a predictive tool to guide and monitor…
ASCO GI 2024: New immunotherapy combinations for patients with oesophageal cancer
Results from a new phase III study found that combining PD-L1 and TIGIT inhibitors plus…
ASCO GI 2024: Adding immunotherapy-based combination to TACE improves progression-free survival in patients with most common liver cancer
The addition of durvalumab and bevacizumab to TACE significantly improved progression-free survival in patients with…
Unpacking Endometrial Cancer with Professor Linda Mileshkin
Endometrial cancer is the most common gynaecological cancer in Australia and advanced disease and early…
ASH 2023: New drug helps narrow racial survival disparity in patients with acute myeloid leukaemia
Non-Hispanic Black patients with acute myeloid leukaemia (AML) are living longer, now that new therapies are available,…